Javascript must be enabled to continue!
Physical Function, Hyperuricemia, and Gout in Older Adults
View through CrossRef
ObjectiveGout prevalence is high in older adults and those affected are at risk of physical disability, yet it is unclear whether they have worse physical function.MethodsWe studied gout, hyperuricemia, and physical function in 5,819 older adults (age ≥65 years) attending the 2011–2013 Atherosclerosis Risk in Communities Study visit, a prospective US population‐based cohort. Differences in lower extremity function (Short Physical Performance Battery [SPPB] and 4‐meter walking speed) and upper extremity function (grip strength) by gout status and by hyperuricemia prevalence were estimated in adjusted ordinal logistic regression (SPPB) and linear regression (walking speed and grip strength) models. Lower scores or times signify worse function. The prevalence of poor physical performance (first quartile) by gout and hyperuricemia was estimated using adjusted modified Poisson regression.ResultsTen percent of participants reported a history of gout and 21% had hyperuricemia. There was no difference in grip strength by history of gout (P = 0.77). Participants with gout performed worse on the SPPB test; they had 0.77 times (95% confidence interval [95% CI] 0.65, 0.90, P = 0.001) the prevalence odds of a 1‐unit increase in SPPB score and were 1.18 times (95% CI 1.07, 1.32, P = 0.002) more likely to have poor SPPB performance. Participants with a history of gout had slower walking speed (mean difference −0.03; 95% CI −0.05, −0.01, P < 0.001) and were 1.19 times (95% CI 1.06, 1.34, P = 0.003) more likely to have poor walking speed. Similarly, SPPB score and walking speed, but not grip strength, were worse in participants with hyperuricemia.ConclusionOlder adults with gout and hyperuricemia are more likely to have worse lower extremity, but not upper extremity, function.
Title: Physical Function, Hyperuricemia, and Gout in Older Adults
Description:
ObjectiveGout prevalence is high in older adults and those affected are at risk of physical disability, yet it is unclear whether they have worse physical function.
MethodsWe studied gout, hyperuricemia, and physical function in 5,819 older adults (age ≥65 years) attending the 2011–2013 Atherosclerosis Risk in Communities Study visit, a prospective US population‐based cohort.
Differences in lower extremity function (Short Physical Performance Battery [SPPB] and 4‐meter walking speed) and upper extremity function (grip strength) by gout status and by hyperuricemia prevalence were estimated in adjusted ordinal logistic regression (SPPB) and linear regression (walking speed and grip strength) models.
Lower scores or times signify worse function.
The prevalence of poor physical performance (first quartile) by gout and hyperuricemia was estimated using adjusted modified Poisson regression.
ResultsTen percent of participants reported a history of gout and 21% had hyperuricemia.
There was no difference in grip strength by history of gout (P = 0.
77).
Participants with gout performed worse on the SPPB test; they had 0.
77 times (95% confidence interval [95% CI] 0.
65, 0.
90, P = 0.
001) the prevalence odds of a 1‐unit increase in SPPB score and were 1.
18 times (95% CI 1.
07, 1.
32, P = 0.
002) more likely to have poor SPPB performance.
Participants with a history of gout had slower walking speed (mean difference −0.
03; 95% CI −0.
05, −0.
01, P < 0.
001) and were 1.
19 times (95% CI 1.
06, 1.
34, P = 0.
003) more likely to have poor walking speed.
Similarly, SPPB score and walking speed, but not grip strength, were worse in participants with hyperuricemia.
ConclusionOlder adults with gout and hyperuricemia are more likely to have worse lower extremity, but not upper extremity, function.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
HYPERURICEMIA AND ITS ASSOCIATION WITH HYPERTENSION: RISK FACTORS AND MANAGEMENT
HYPERURICEMIA AND ITS ASSOCIATION WITH HYPERTENSION: RISK FACTORS AND MANAGEMENT
Hyperuricemia is a medical condition that arises due to the increased concentration of uric acid in the body. Worldwide, a surge in the number of hyperuricemia cases has been seen ...
Associations of metal exposure with hyperuricemia and gout in general adults
Associations of metal exposure with hyperuricemia and gout in general adults
BackgroundEpidemiological evidence of the associations between metal exposure and gout-related outcomes (including serum uric acid [SUA], hyperuricemia and gout) is scarce. The aim...
Hypertension and gout: A Mendelian randomization study
Hypertension and gout: A Mendelian randomization study
Abstract
Background: Although there is solid epidemiological evidence supporting the connection between hypertension and gout, the causal relationship and direction associa...
A u-shape association of serum uric acid with gout in US adults
A u-shape association of serum uric acid with gout in US adults
AbstractBackgroundSerum uric acid (SUA) level is the strongest determinant of gout, and the relationship between hyperuricemia and gout has been found. However, the association bet...
Association between the aggregate index of systemic inflammation and hyperuricemia: evidence from NHANES 2011–2018
Association between the aggregate index of systemic inflammation and hyperuricemia: evidence from NHANES 2011–2018
Abstract
Objective
The aim of this study was to explore the association between the Aggregate Index of Systemic Inflammation (AISI) and hyperuricemia, using data from the ...
Study on the diagnosis of gout with xanthine and hypoxanthine
Study on the diagnosis of gout with xanthine and hypoxanthine
BackgroundHyperuricemia is the only biochemical index in the classification of acute gouty arthritis in American Rheumatism Association 1977 and the main basis of clinical diagnosi...
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
Cardiovascular diseases (CVDs) are the fastest-growing cause of death around the world, and atherosclerosis plays a major role in the etiology of CVDs. The most recent figures show...

